DICLOFENAC POTASSIUM 50 MG + PARACETAMOL 325 MG + CHLORZOXAZONE 250 MG is a three-component oral solid dosage formulation containing Diclofenac Potassium, Paracetamol and Chlorzoxazone. The development of a combination tablet with three active pharmaceutical ingredients requires controlled formulation design, compatibility assessment and precise manufacturing practices. Each ingredient has different physicochemical characteristics, making uniform blending and consistent compression important considerations. For pharmaceutical companies building a PCD Pharma Franchise portfolio, this combination can be incorporated into an organized range of pharmaceutical tablets with defined quality specifications and professional packaging.
The formulation contains Diclofenac Potassium 50 mg, Paracetamol 325 mg and Chlorzoxazone 250 mg in the specified tablet composition. Because the three active ingredients are present at different quantities, formulation development must focus on maintaining uniform distribution throughout the tablet blend.
A suitable excipient system may include diluents, binders, disintegrants, lubricants and glidants, depending on the selected manufacturing approach. The excipients are chosen according to their functional properties, compatibility with the active ingredients and influence on tablet performance.
Preformulation studies may be carried out to evaluate parameters such as particle size, bulk density, flowability, moisture characteristics and compatibility. These studies help determine an appropriate manufacturing process and excipient combination.
The final formulation is designed to provide a consistent tablet matrix with controlled physical characteristics and appropriate distribution of all three active pharmaceutical ingredients.
Uniform blending becomes particularly important in DICLOFENAC POTASSIUM 50 MG + PARACETAMOL 325 MG + CHLORZOXAZONE 250 MG because the formulation combines three active components with different quantities and potentially different powder characteristics.
Raw materials are first evaluated against their respective quality specifications. Depending on the material properties, sieving, milling or other particle-size adjustment processes may be considered to achieve suitable powder characteristics.
A defined blending sequence can be established during process development. Pre-blending of selected ingredients may be used where necessary to improve distribution, especially when one component is present at a comparatively lower concentration.
The blending process should be controlled for time, speed, equipment loading and material sequence. Excessive blending can sometimes affect powder characteristics, while inadequate blending may result in non-uniform distribution.
Representative samples may be collected from different locations within the blend and analyzed for the presence and distribution of the active ingredients. This helps establish whether the blend is suitable for subsequent compression.
Once the blend meets established in-process requirements, it can be transferred to an appropriate tablet compression system. Compression parameters are optimized according to the formulation's flow, density and compaction behavior.
Machine speed, compression force, feeder settings and tooling configuration can influence tablet weight, thickness, hardness and friability. These parameters therefore require controlled adjustment during process development.
In-process testing may include tablet weight variation, physical appearance, thickness and hardness. Friability assessment can provide additional information about the mechanical strength of the compressed tablets.
If the product is developed as a coated tablet, an additional coating stage may be incorporated. Coating parameters such as spray rate, coating suspension properties, drying conditions and weight gain can be controlled to maintain consistent coverage.
Process validation and continued in-process monitoring help establish reproducibility across manufacturing batches.
Quality evaluation of this three-component tablet involves both physical testing and chemical analysis. Each active pharmaceutical ingredient requires appropriate identification and quantitative assessment according to the finalized product specifications.
Validated analytical methods may be used to determine the assay of Diclofenac Potassium, Paracetamol and Chlorzoxazone. Since multiple active ingredients are present, analytical procedures should provide suitable selectivity and accuracy for individual component measurement.
Finished tablets may be evaluated for appearance, average weight, weight variation, hardness, friability and disintegration. Dissolution testing can also be incorporated into the quality-control program to evaluate the release characteristics of the formulation under defined laboratory conditions.
Where applicable, content uniformity testing provides additional information about consistency between individual dosage units. Related substances and degradation products may also be monitored as part of the established stability and quality-control program.
All analytical and physical tests should be performed according to validated procedures and predefined specifications.
Stability studies are an important part of the development of DICLOFENAC POTASSIUM 50 MG + PARACETAMOL 325 MG + CHLORZOXAZONE 250 MG. Because the formulation contains multiple active pharmaceutical ingredients, stability evaluation should monitor the characteristics of each component as well as the overall tablet system.
Depending on the product specification, stability parameters may include appearance, assay, dissolution, degradation products, moisture-related characteristics and other relevant quality attributes.
Suitable pharmaceutical packaging can help protect the tablets from environmental exposure during storage and transportation. Blister packs, strip packs or other compatible packaging formats may be selected based on the formulation and stability requirements.
The packaging material should provide an appropriate barrier against moisture, light and other environmental factors where relevant. Container compatibility and pack integrity may also be evaluated during product development.
Stability data can be used to establish suitable storage conditions and support the proposed shelf life of the finished product.
DICLOFENAC POTASSIUM 50 MG + PARACETAMOL 325 MG + CHLORZOXAZONE 250 MG can form part of a diversified pharmaceutical portfolio containing combination tablets and other dosage forms. Maintaining standardized product specifications, packaging formats and documentation can help pharmaceutical companies manage their product range systematically.
For a PCD Pharma Franchise portfolio, the formulation can be presented with clear information regarding product name, active composition, strength, packing configuration, manufacturer details and other approved product information. Professional packaging and consistent product documentation can support organized portfolio management.
A combination tablet containing three active ingredients requires careful coordination between formulation development, raw-material qualification, blending, compression, analytical testing, stability assessment and packaging. Each stage contributes to the consistency and quality of the final dosage form.
Overall, DICLOFENAC POTASSIUM 50 MG + PARACETAMOL 325 MG + CHLORZOXAZONE 250 MG represents a multi-active oral tablet formulation that benefits from controlled particle processing, optimized blending, precise compression and comprehensive quality evaluation. Appropriate stability planning and packaging selection further support the maintenance of product quality throughout the intended shelf life, allowing the formulation to be integrated into a professionally managed pharmaceutical and PCD Pharma Franchise product portfolio.
We combine quality, innovation, and strong distribution to help our partners grow successfully in the pharma market.
The company is offering business opportunity for scalable and sustainable returns to its associates. We are engaged in discovery, development and commercialization of pharmaceutical medicine keeping in mind its quality and affordability.
© Novolilly 2025. All Rights Reserved – Developed & Managed By Kavir Infotech